Abbott Korea launched 'iDECIDE' anti-obesity campaign

Published: 2004-08-11 06:58:00

Updated: 2004-08-11 06:58:00

Abbott Korea, which has marketed its weight loss drug Reductil since 2001, has announced that it is starting a new anti-obesity online campaign entitled 'iDECIDE', with an aim to publicize the importance of obese patients' strong will in the course of treatment and deliver a message from healthca...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK